US Stock Movement: Xeris Biopharma surged on October 5th due to acquisition interest, Phase III results for XP-8121, and revenue growth

Xeris Biopharma's Significant Surge on October 5 Explained

Keywords: acquisition interest, XP-8121 Phase III, revenue growth

1. On September 29, it was reported that H Lundbeck had been working with advisors to evaluate the possibility of acquiring Xeris. The discussions remain in the preliminary stages; Xeris stated that the company is "not for sale" and will continue to develop and commercialize its therapeutic product portfolio.

2. On September 9, the company stated that the registrational Phase III study plan for XP-8121 is scheduled to commence on time at the end of 2026, with primary results expected to be announced in the second half of 2028. FDA approval and commercialization in the United States is anticipated for 2030, with peak net revenue potential estimated between $1 billion and $3 billion.

3. On August 6, the company announced total revenue of $92.1 million for the second quarter, a 29% year-on-year increase; net product revenue reached $91 million, a 34% year-on-year increase. Among these, Recorlev’s net revenue was $56.8 million, up 81% year-on-year, and full-year total revenue guidance for 2026 was adjusted to $385 million to $390 million.

(Disclaimer: This content is generated by AI technology based on the summary of publicly available information, for reference only and does not constitute investment advice.)